Back to Search

A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime

  • Protocol Number: 201110144
  • Principal Investigator: Shenoy, Shalini
  • Cancer Types: Siteman Kids- Pediatrics

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.

Protocol Interventions

Drug: Treatment Plan 2: Strata 2, 3, or 4, Drug: GVHD Regimen A: UCB Recipients, Drug: GVHD Regimen B: BM Recipients